Jenkins George M, a director at Palvella Therapeutics, Inc. (NASDAQ: PVLA), acquired 4,000 shares of the company’s common stock on February 27, 2026, paying $125 per share, according to a Form 4 filing with the Securities and Exchange Commission. The purchase outlay totaled $500,000.
Following the transaction, the filing reports Jenkins holds 187,171 shares directly. He also has an indirect stake of 13,516 shares held through a foundation.
At the time of this report, PVLA shares were trading at $135.02, a level that reflects a 597% return over the past 12 months. However, InvestingPro analysis included in market commentary suggests the stock may be overvalued at current levels.
Alongside the insider purchase, Palvella recently completed a sizable public offering that raised $230 million in gross proceeds. The company sold 1,840,000 shares at $125 each, with underwriters exercising their full option to buy an additional 240,000 shares. The offering was managed by a syndicate that included TD Cowen, Cantor, and Stifel.
Palvella had initially announced a $150 million public stock offering with a 30-day option for underwriters to purchase additional shares, but the final transaction exceeded that earlier figure after the underwriters exercised their full allotment.
Separately, Truist Securities increased its price target for Palvella to $210 and maintained a Buy rating. The firm cited a higher probability of success for Palvella’s QTORIN Rapamycin treatment following positive phase 3 results. The probability of success for the treatment is reported at 90%.
Collectively, the insider purchase, the upsized equity raise, and the analyst action reflect a period of both financial activity and clinical progress for the company. For investors seeking additional valuation and financial detail, a comprehensive Pro Research Report covering PVLA and more than 1,400 other U.S. equities is available.
These developments signal concurrent capital markets engagement and an apparent vote of confidence from a company director, juxtaposed with third-party analysis flagging potential overvaluation at the current trading level. Observers should weigh the insider transaction, the large offering, and the clinical-readout-driven analyst update together when assessing Palvella’s near-term profile.